News & Events

Upcoming Events

Tue, 5/24/2022 - 12:00 PM ET
For patients/survivors - Join us every Tuesday for this general… more
Thu, 5/26/2022 - 8:00 PM CT
For caregivers, family & friends - You don’t need to take on… more
Fri, 5/27/2022 - 6:30 PM
For patients/survivors - General meetup moderated by survivors After… more
Tue, 5/31/2022 - 12:00 PM ET
For patients/survivors - Join us every Tuesday for this general… more
May 19, 2022

CHMP recommends EU approval of Roche’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer

May 19, 2022

CHMP recommends EU approval of Roche’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer

May 19, 2022

Bristol Myers Squibb Data at ASCO and EHA 2022 Highlight Progress in Transforming Treatment for Patients with Cancer and Blood Disorders

May 19, 2022

Bristol Myers Squibb Data at ASCO and EHA 2022 Highlight Progress in Transforming Treatment for Patients with Cancer and Blood Disorders

May 18, 2022

Immunotherapy in NSCLC With Classical EGFR Mutations or ALK Rearrangements

May 18, 2022

Immunotherapy in NSCLC With Classical EGFR Mutations or ALK Rearrangements

May 18, 2022

Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA

May 18, 2022

Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA

May 17, 2022

Discovering a New Approach to Treat Metastatic NSCLC

May 17, 2022

Discovering a New Approach to Treat Metastatic NSCLC

Lung cancer continues to be the number-one cause of cancer deaths in the United States. In the past decade, we have seen great improvements in the treatment of metastatic lung cancer with targeted therapies and immunotherapy. “When targeted therapies aren’t an option, the current standard of care for patients is immunotherapy alone or in combination with chemotherapy. But many patients don’t respond to these treatments the way we’d like them to,” said Sean Pitroda, MD, assistant professor of…
May 17, 2022

An immune gene signature to predict prognosis and immunotherapeutic response in lung adenocarcinoma

May 17, 2022

An immune gene signature to predict prognosis and immunotherapeutic response in lung adenocarcinoma

May 9, 2022

Survival Varies Little by Surgery Type in NSCLC With Micro Lesions

May 9, 2022

Survival Varies Little by Surgery Type in NSCLC With Micro Lesions

May 9, 2022

Segmentectomy “Should Be Standard” for Early-Stage Non-Small Cell Lung Cancer

May 9, 2022

Segmentectomy “Should Be Standard” for Early-Stage Non-Small Cell Lung Cancer

May 9, 2022

A Novel Immune-Prognosis Index Predicts the Benefit of Lung Adenocarcinoma Patients

May 9, 2022

A Novel Immune-Prognosis Index Predicts the Benefit of Lung Adenocarcinoma Patients

May 2, 2022

Tips for Better Sleep

May 2, 2022

Tips for Better Sleep

Sleep tips session with our sleep expert, Peggy Burhenn.